11/20
03:11 am
ebs
Emergent BioSolutions Inc. (NYSE: EBS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Emergent BioSolutions Inc. (NYSE: EBS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/8
10:19 am
ebs
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/7
02:11 pm
ebs
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 [Yahoo! Finance]
Medium
Report
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 [Yahoo! Finance]
11/7
10:39 am
ebs
Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $8.00 to $12.00. They now have a "buy" rating on the stock.
High
Report
Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $8.00 to $12.00. They now have a "buy" rating on the stock.
11/7
01:28 am
ebs
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/6
05:06 pm
ebs
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa [Yahoo! Finance]
Medium
Report
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa [Yahoo! Finance]
11/6
04:49 pm
ebs
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
Medium
Report
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
11/6
04:22 pm
ebs
Emergent BioSolutions Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Emergent BioSolutions Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/6
04:05 pm
ebs
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
Medium
Report
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
11/4
07:30 am
ebs
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
Low
Report
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
10/25
09:00 am
ebs
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS
Low
Report
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS
10/23
07:30 am
ebs
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
Medium
Report
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
10/8
05:40 pm
ebs
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic [Yahoo! Finance]
Medium
Report
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic [Yahoo! Finance]
10/8
05:32 pm
ebs
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
Medium
Report
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
10/4
09:51 am
ebs
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario [Seeking Alpha]
Medium
Report
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario [Seeking Alpha]
10/2
07:30 am
ebs
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
Medium
Report
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
9/27
11:18 am
ebs
Amazon to provide opioid overdose drug in workplace [Seeking Alpha]
Low
Report
Amazon to provide opioid overdose drug in workplace [Seeking Alpha]
9/26
08:05 am
ebs
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
High
Report
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
9/25
07:44 am
ebs
Emergent Bio gains after confirming $400M orders for 2024/25 [Seeking Alpha]
High
Report
Emergent Bio gains after confirming $400M orders for 2024/25 [Seeking Alpha]
9/25
07:17 am
ebs
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts [Yahoo! Finance]
High
Report
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts [Yahoo! Finance]
9/25
07:07 am
ebs
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
Medium
Report
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
9/24
11:19 am
ebs
Emergent BioSolutions Inc.'s (NYSE:EBS) institutional investors lost 16% last week but have benefitted from longer-term gains [Yahoo! Finance]
Low
Report
Emergent BioSolutions Inc.'s (NYSE:EBS) institutional investors lost 16% last week but have benefitted from longer-term gains [Yahoo! Finance]
9/13
12:10 pm
ebs
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $16.00 price target on the stock.
Low
Report
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $16.00 price target on the stock.
9/13
06:57 am
ebs
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation [Yahoo! Finance]
Medium
Report
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation [Yahoo! Finance]
9/13
06:45 am
ebs
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
Medium
Report
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation